High Oleic Soybean Oil (Unhydrogenated)
Colorectal Neoplasm
Explore 117 assets in Colorectal Neoplasm →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Academia Sinica, Taiwan
Modality
mixture
Development Phase
N/A
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| High Oleic Soybean Oil (Unhydrogenated) (this asset) | Academia Sinica, Taiwan | N/A | D · 30 |
| Fluorouracilum | Rutgers, The State University of New Jersey | P4 | BBB |
| Oxaliplatin | Peking University Cancer Hospital & Institute | P4 | BBB |
| Irinotecan | Shanghai Zhongshan Hospital | P4 | BBB |
| Regorafenib | Sergey Orlov, MD | P4 | BB |
| Capecitabine | Rutgers, The State University of New Jersey | P4 | BB |
| Ferric Carboxymaltose [Ferinject] | Nottingham University Hospitals NHS Trust | P4 | BB |
| Vandazole | Helsinki University Central Hospital | P4 | BB |
| Nivolumab | Bristol-Myers Squibb | P3 | BB |
+41 more in the Colorectal Neoplasm cohort
Other indications for High Oleic Soybean Oil (Unhydrogenated)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Obesity Disorder | — | Early P1 | C · 39 |
| Cardiovascular Disorder | — | N/A | D · 30 |
| Diabetes Mellitus | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. High Oleic Soybean Oil (Unhydrogenated) in Colorectal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/high-oleic-soybean-oil-unhydrogenated-colorectal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →